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Abstract
Background: Given the implication of histone acetylation in memory processes, histone deacetylase inhibitors
(HDACIs) have been postulated as potential modulators of cognitive impairment in Alzheimer’s disease (AD).
However, dose-dependent side effects have been described in patients with the currently available broad-spectrum
HDACIs, explaining why their therapeutic potential has not been realized for chronic diseases. Here, by
simultaneously targeting two independent enzyme activities, histone deacetylase (HDAC) and phosphodiesterase-5
(PDE5), we propose a novel mode of inhibitory action that might increase the therapeutic specificity of HDACIs.
Results: The combination of vorinostat, a pan-HDACI, and tadalafil, a PDE5 inhibitor, rescued the long-term
potentiation impaired in slices from APP/PS1 mice. When administered in vivo, the combination of these drugs
alleviated the cognitive deficits in AD mice, as well as the amyloid and tau pathology, and it reversed the reduced
dendritic spine density on hippocampal neurons. Significantly, the combination of vorinostat and tadalafil was more
effective than each drug alone, both against the symptoms and in terms of disease modification, and importantly,
these effects persisted after a 4-week washout period.
Conclusions: The results highlight the pharmacological potential of a combination of molecules that inhibit HDAC
and PDE5 as a therapeutic approach for AD treatment.
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Background
There is now considerable evidence that epigenetic regula-
tion is a dynamic and critical mechanism modulating
neuronal function. It was recently suggested that memory
impairment in Alzheimer’s disease (AD) is caused by a
“reversible” epigenetic blockade of gene transcription [1].
One epigenetic mechanism that regulates gene transcrip-
tion is histone acetylation, a modification that is known to
enhance or constrain cognitive functions. In fact, from a
therapeutic point of view, histone deacetylase inhibitors
(HDACIs) have emerged as promising compounds that
might help manage AD. However, the toxicity associated
with HDACIs has limited the clinical data available, a
phenomenon that may have an important impact in pa-
tients receiving long-term therapy [2]. In order to reduce
side effects while maintaining cognitive benefits, one strat-
egy would be to develop isoform-selective HDACIs. How-
ever, since the side effects reported for HDACIs in
humans are dose dependent [3], the use of lower doses of
pan-HDAC inhibitors to reduce their toxicity could repre-
sent another solution, combining them with other AD-
related drugs to obtain a compound or synergistic effect.
Targeting multiple elements in the network under-
lying AD may produce benefits beyond those of repre-
sentative monotherapies. Accordingly, for the first
time, we propose here a new therapeutic approach to
treat AD that targets two independent but synergistic
pathways related to different aspects of the disease.
Specifically, we propose combining the inhibition of
HDACs with that of phosphodiesterase-5 (PDE5), an
enzyme that targets another intracellular pathway in-
volved in memory formation and other AD-related
features [4–6]. PDE5 inhibitors regulate signalling
pathways by elevating cGMP, and they may ultimately
promote gene transcription by directly and/or indir-
ectly activating binding to the cAMP response element
(CREB) [7]. CREB plays an essential role in regulating
the transcription of genes involved in the consolida-
tion of long-term memories [8, 9]. Moreover, its inter-
action with the CREB-binding protein (CBP) improves
memory and enhances synaptic plasticity through
HDAC inhibition [10]. Hence, the activation of CREB
would be expected to further potentiate the enhance-
ment of memory and synaptic plasticity induced by
HDACIs [11]. In line with this idea, PDE5 inhibitors
could drive the gene transcription induced by histone
acetylation to favour that of CREB-dependent memory-
related genes, avoiding global transcriptional activation.
Likewise, and due to “epigenetic priming” [12], HDACIs
may sensitize the cell’s response to PDE5 inhibitors, facili-
tating the transcription of CREB-dependent genes and
thereby improving therapeutic selectivity.
To assess the potential therapeutic value of concomitant
HDAC and PDE5 inhibition in AD, we used the HDACI
vorinostat and the PDE5 inhibitor tadalafil as reference
compounds. A synergism between these two inhibitors
when co-administered at sub-effective doses was not only
achieved in terms of memory function but also in reducing
the amyloid pathology. Thus, the concomitant inhibition of
HDAC and PDE5 may represent a novel symptomatic and
disease-modifying strategy to treat AD.
Results
The concomitant inhibition of HDAC and PDE5 has a
synergistic effect on histone acetylation
Using primary neuronal cultures, we tested whether the
combination of vorinostat (a class I and class IIb
HDAC inhibitor) and tadalafil (a PDE5 inhibitor) had a
synergistic effect on the induction of histone 3 acetyl-
ation at lys9 (AcH3K9), an epigenetic mark implicated
in memory enhancement in mice [13, 14]. When we
exposed the cultured neurons to different concentrations
of vorinostat and tadalafil for 2 h (10, 100 and 500 nM),
we detected a strong induction of AcH3K9 by vorinostat
at concentrations of 100 and 500 nM, whereas no effect
was found with tadalafil (Fig. 1a). Interestingly, we ob-
served a synergistic effect on this epigenetic mark when
vorinostat (50 nM) was administered in combination with
tadalafil (50 and 200 nM: Fig. 1b). This synergistic effect
was confirmed in the SH-SY5Y neuroblastoma cell line
and using alpha technology, where AcH3K9 was induced
significantly by vorinostat (50 nM) combined with tadalafil
(from 160 nM: Fig. 1e; compared with each compound
alone in Fig. 1c, d). These data suggest that PDE5 inhib-
ition may provoke CREB phosphorylation and, in turn, the
recruitment of CBP, thereby enhancing histone acetylation
and memory-related gene transcription (Fig. 1f).
Concomitant inhibition of HDAC and PDE5 had a
synergistic effect on long-term potentiation in APP/PS1
transgenic mice
To evaluate the physiological consequences of vorino-
stat and tadalafil treatment, we first investigated their
effects by monitoring long-term synaptic plasticity
(LTP), a well-known cellular mechanism that underlies
memory processes [15]. Extracellular synaptic activity
was recorded in hippocampal slices from APP/PS1
adult mice (7–9 months), showing that the LTP induc-
tion protocol evoked similar synaptic potentiation after
a brief application of vorinostat (2 μM) to that of con-
trol slices treated with the vehicle alone. Likewise, tada-
lafil (50 nM) preincubation did not significantly affect
the degree of LTP in APP/PS1 slices (Fig. 2a, b), yet in-
cubation with a combination of vorinostat and tadalafil
did produce robust potentiation of synaptic transmis-
sion (Fig. 2a, b), significantly beyond that obtained by
application of each inhibitor alone. By contrast, the
combination of both inhibitors did not affect LTP in
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APP/PS1-negative slices compared with control condi-
tions (Fig. 2c, d). Therefore, HDAC and PDE5 inhibi-
tors would appear to have a synergistic effect on LTP in
AD mice.
The effects of vorinostat and tadalafil combination
therapy on memory function in aged Tg2576 mice
A 2–3-week treatment with vorinostat (50 mg/kg) re-
stored contextual memory deficits in the APPswe/PS1dE9
AD mouse model [16], and likewise, tadalafil (15 mg/kg)
improves memory deficits in an aged AD mouse model
[17]. Thus, we tested whether the combined administra-
tion of lower doses of both of these compounds could
restore cognitive deficits in the Tg2576 AD mouse model.
To test this hypothesis, we treated 14–16-month-old
Tg2576 mice for 4 weeks with tadalafil (1 mg/kg, p.o.) and
vorinostat (12.5 mg/kg, i.p.), with either inhibitor alone
(tadalafil [1 mg/kg, p.o.] or vorinostat [12.5 mg/kg, i.p.]),
or with the vehicle alone (10 % DMSO) daily. We
performed an initial pharmacokinetic study of the admin-
istration of vorinostat, tadalafil or combined vorinostat
and tadalafil at these doses in plasma and brain samples.
The brain/plasma ratios 20 min after combined vorinostat
and tadalafil administration were 11 % for tadalafil and
5.5 % for vorinostat, corresponding to brain concentra-
tions of 30 and 345.5 nmol/kg (Additional file 1: Figure S1
and Table S1).
Memory function was assessed during the second and
third week of treatment using two hippocampal-dependent
tasks, contextual fear conditioning (FC) and Morris water
maze (MWM) tests, respectively (see scheme in
Fig. 3a). Compared to wild-type (WT) mice, Tg2576
mice exhibited severe disruption in freezing behaviour in
the FC test 24 h after training (t(19,2) = 5.3, p ≤ 0.001)
(Additional file 1: Figure S2a). Memory impairment was
rescued to a significant extent by a combined 2-week treat-
ment with vorinostat and tadalafil (F(3,44) = 2.7, p ≤ 0.05),
whereas neither of these drugs alone restored fear memory
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Fig. 1 A synergistic effect was observed with the combination of vorinostat and tadalafil on histone 3 acetylation. a Western blot analysis
showing histone 3 acetylation (AcH3-K9) levels in primary neuronal culture treated with vorinostat or tadalafil for 2 h (*p ≤ 0.05). Actin was used
for normalization. b Western blot analysis showing AcH3-K9 levels in primary neuronal culture treated with vorinostat and different concentrations
of tadalafil for 2 h (*p ≤ 0.05, ***p≤ 0.001). Actin was used for normalization. c–e Detection of cellular AcH3-K9 was assayed using SHSY-5Y cells
and AlphaLisa technology. SHSY-5Y cells were treated with vorinostat or tadalafil in c and d or the combination in e for 2 h (**p ≤ 0.01,
***p ≤ 0.001). Histone 3 (H3) was used for normalization. In all figures, data are represented as mean ± SEM expressed as fold change
versus control vehicle-treated cultures (n = 3–4 per condition). f Scheme showing a possible synergistic effect with HDAC and PDE inhibition.
Ac acetyl, HDAC histone deacetylase, HAT histone acetyl transferase, CRE cAMP responsive element, CREB CRE-binding protein, CBP CREB-binding
protein, P phospho, PDE phosphodiesterase.
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(Fig. 3b). In the MWM, no significant differences were ob-
served among the experimental groups during the visible-
platform training phase, indicating that the animals had a
comparable ability to perform the task (Additional file 1:
Figure S2b). However, Tg2576 animals (14–16 months old)
showed severe cognitive impairment in both the acquisi-
tion phase (significant main effect of genotype F(1,29) = 13,
p ≤ 0.001) and during the probe test on days 7 (t(29) =
2, p = 0.05) and 9 (t(29) = 2.2, p ≤ 0.05: Additional file 1:
Figure S2c and 2d). Notably, the combination of vorino-
stat and tadalafil rescued these memory deficits, evident
through the lower escape latencies in the acquisition
phase (F(3,316) = 21.3, p ≤ 0.001: Fig. 3c). Interestingly, the
group receiving only vorinostat also had lower escape la-
tencies compared to the mice that received the vehicle
alone (F(3,316) = 21.3, p ≤ 0.001: Fig. 3c). Nevertheless,
during the retention phase on day 9, only the animals that
received the combination of vorinostat and tadalafil spent
significantly more time than vehicle-treated animals in the
correct quadrant (F(3,36) = 2.9, p ≤ 0.05), demonstrating a
synergistic effect of the two drugs on spatial memory re-
tention (Fig. 3d).
Finally, the drug treatments were followed by a
washout period of 4 weeks, after which mice were re-
trained in a reversal phase of the MWM test, placing
the platform in the opposite quadrant. The hidden
platform training was carried out over 5 days (four
trials per day) and followed by a memory retention
probe test on day 6. Tg2576 mice treated with the
vehicle performed worse than WT mice in both the
acquisition (F(1, 28) = 7.0, p ≤ 0.01: Additional file 1:
Figure S2e) and the retention phase on day 6 (t(29) =
2.8, p ≤ 0.01: Additional file 1: Figure S2f ). By con-
trast, these transgenic mice treated with the combin-
ation therapy displayed a significantly shorter escape
latency than the control Tg2576 mice that received
the vehicle alone (F(3,196) = 10.5, p ≤ 0.001: Fig. 3e).
Once again, the animals that received vorinostat alone
also showed lower escape latencies than the Tg2576
mice that receive the vehicle alone (F(3,196) = 10.5,
d
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Fig. 2 A synergistic effect was observed with the combination of vorinostat and tadalafil on long-term potentiation (LTP) in APP/PS1 mice
slices. a Relative fPSP slope (from basal values) versus time in hippocampal APP/PS1-positive slices. Orange vertical bar denotes time for
vorinostat (2 μM ) and/or tadalafil (50 nM) incubation; arrow corresponds to the high-frequency stimulation (HFS) protocol. b Average rela-
tive changes of fPSP slope before and 60 min after HFS in control (dark grey; n = 6) and vorinostat (green; n = 5), tadalafil (light grey; n = 4),
and vorinostat and tadalafil (combination, blue; n = 5) treatments. c Relative fPSP slope (from basal values) versus time in APP/PS1-negative
slices in control (black) and the combination of vorinostat and tadalafil (blue) conditions. Orange vertical bar denotes time for the combination of vorinostat
and tadalafil (combination) incubation; arrow corresponds to HFS. d Average relative changes of fPSP slope before (open bars) and 60 min after HFS (filled
bars) in control (black) and combination treatment (blue) in APP/PS1-negative mice (n= 8 and 3 slices, respectively); *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001. Data
are represented as means ± SEM
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p ≤ 0.05: Fig. 3e). During the probe test, only the
group of animals receiving the combination of vorinostat
and tadalafil spent significantly more time in the target
quadrant compared with the vehicle-treated mice (F(3,36)
= 4.0, p ≤ 0.05: Fig. 3f). Together, these results indicate
that combination therapy of vorinostat and tadalafil dur-
ing 4 weeks restored memory impairment in aged Tg2576
mice whose cognition was severely affected. Furthermore,
this effect was maintained after a 4-week washout period.
Interestingly, the treatment with vorinostat enhances the
learning capacity of transgenic mice, yet memory was not
consolidated by this drug alone since no differences were
detected between Tg2676 mice receiving the vehicle alone
or vorinostat during the probe tests.
a b
c d
e f
Fig. 3 Chronic treatment (4 weeks) with the combination of vorinostat and tadalafil reversed learning deficits in aged Tg2576 mice. a Scheme
showing timeline for treatment, behavioural tasks and sacrifice of mice. FC fear conditioning, MWM Morris water maze. b Freezing behaviour from
Tg2576 mice treated with vehicle, vorinostat, tadalafil or the combination (vorinostat and tadalafil) (*p≤ 0.05). Data represent the percentage of
time freezing during a 2-min test. In this and all subsequent figures, results are expressed as mean ± SEM (n = 10–12 per group). c Escape latency
of the hidden platform in the MWM test for the Tg2576 mice treated with vehicle, vorinostat, tadalafil or combination (***p≤ 0.001, Tg2576 mice
treated with the combination versus Tg2576 vehicle; ###p≤ 0.001, Tg2576 mice treated with the combination versus Tg2576 tadalafil; ¥¥¥ p ≤
0.001, Tg2576 treated with vorinostat versus Tg2576 vehicle). d Percentage of time spent in correct quadrant of the probe test (days 4, 7 and 9)
(*p≤ 0.05). e Escape latency in the reversal MWM test for the Tg2576 mice treated with vehicle, vorinostat, tadalafil or combination after the
washout period (***p≤ 0.001 Tg2576 mice treated with the combination versus Tg2576 vehicle) (¥¥¥p≤ 0.001 Tg2576 treated with vorinostat
versus Tg2576 vehicle). f Percentage of time spent in correct quadrant during the probe test (day 6) (*p≤ 0.05)
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Effects of vorinostat and tadalafil combination therapy on
pathological AD markers in aged Tg2576 mice
Aβ42 was assessed in protein extracts from the parieto-
temporal cortex of Tg2576 treated mice by ELISA, and a
marked decrease in Aβ42 was observed in the mice that
received the combination therapy compared to those that
received the vehicle alone (F(3,36) = 3.3, p ≤ 0.05: Fig. 4a).
By contrast, no significant differences were found between
the mice that received vorinostat or tadalafil and those
treated with the vehicle alone (Fig. 4a). Based on the
significant decrease in Aβ42 in the animals that received
the combination therapy, we explored APP processing in
Western blots of the same extracts. No significant differ-
ences were found in APP (Fig. 4b) or in the APP C-
terminal C99 fragment (CTF: Fig. 4c) between the Tg2576
mice that received the combination therapy or the vehicle
alone. We also analyzed the tau phosphorylation in the
same extracts using a pTau-specific (Ser-202/Thr-205)
antibody normalized to total tau (T46). Compared to WT
mice, there was a significant increase in pTau levels
(t(7,1) = −3.3, p ≤ 0.01: Additional file 1: Figure S3a) in
Tg2576 mice, which decreased following vorinostat
treatment (F(3,11) = 8.7, p ≤ 0.05: Fig. 4d). This effect
was even more pronounced in the mice that received
tadalafil or the combination therapy (F(3,11) = 8.7, p ≤ 0.01).
No significant changes were observed in total tau relative
to actin among the experimental groups.
We also tested whether the behavioural recovery
induced by the combination therapy reflected structural
changes, such as the density of dendritic spines. The
density of spines on hippocampal CA1 pyramidal neu-
rons was analyzed in Tg2576 mice and their WT
a
d e
cb
Fig. 4 Chronic treatment (4 weeks) with the combination of vorinostat and tadalafil reversed the AD histopathological markers in aged Tg2576 mice. a
Aβ42 levels determined by ELISA in parieto-temporal cortex of Tg2576 mice treated with vehicle, vorinostat, tadalafil, or combination (vorinostat and
tadalafil) (n = 8–10 per group) (*p≤ 0.05). In this and all subsequent figures, results are expressed as mean ± SEM. Effects of chronic administration of
vorinostat and tadalafil on full-length APP (b) or C-terminal fragment C99 (c) levels, normalized to actin, in SDS parieto-cortical extracts. The histogram
shows the quantification of the immunochemically reactive bands in the Western blot (representative bands are shown). Data are expressed as the fold
change versus Tg2576 mice receiving vehicle (n= 8–10 in each group). d Representative Western blot bands using the antibody AT8 (pTau), normalized
to total tau (T46) of cortical tissues are shown. The histograms represent the quantification of the immunochemically reactive bands in the Western blot.
Data are expressed as the fold change versus Tg2576 mice receiving vehicle (n = 8–10 in each group) (*p≤ 0.05; **p≤ 0.01). e Representative Golgi
staining images of apical dendrites on CA1 hippocampal pyramidal neurons. Scale bar, 10 μm. The histograms represent the quantification of spine
density of apical dendrites on hippocampal CA1 pyramidal neurons from Tg2576 mice treated with vehicle, vorinostat, tadalafil or combination (vorinostat
and tadalafil) (n= 34–36 neurons from three to four animals per group) (***p≤ 0.001)
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littermates using an optimized Golgi impregnation
method. In line with previous findings [18], a signifi-
cantly lower density of apical dendrites was found on
CA1 pyramidal neurons in Tg2576 mice than in WT
mice (t(70) = 3.9, p ≤ 0.001: Additional file 1: Figure S3b),
while treatment with tadalafil, vorinostat or the combin-
ation of these drugs reversed the deficit in spine density
on apical CA1 dendrites, which returned to control
values (F(3,141) = 12.6, p ≤ 0.001: Fig. 4e). These results
suggest that the reduction in spine density is reversible
even long after disease onset, which might account for
the memory improvement observed and maintained for
4 weeks after washout. However, other mechanisms may
influence memory recovery since the effect on dendritic
spine density in the mice that receive tadalafil alone was
not correlated with the behavioural data.
Gene expression induced by vorinostat, tadalafil and the
combination of the two in the hippocampus of Tg2576
mice
To better define the pathways and networks enhanced by
the different treatments, we adopted a non-parametric
approach implemented in the Gene Set Enrichment Ana-
lysis (GSEA) software to determine the genes upregulated
by these drugs [19]. GSEA allowed us to determine the
pathways and gene signatures enriched among 95 gene
sets selected on the basis of memory function and related
to AD. GSEA was carried out on the ranked lists reflecting
the changes in the microarray studies performed, and the
enriched gene sets included those participating in aging
and AD-related cellular processes and pathways (reactome
amyloids, aging brain, highly calcium permeable postsyn-
aptic nicotinic acetylcholine receptors, among others),
providing evidence for an AD-related phenotype. Except
for the mice that received vorinostat, several of the gene
sets enriched by the other treatments were connected dir-
ectly with CREB-dependent genes (M15359, combination
versus saline, p = 0.008 and tadalafil versus saline, p = 0.002;
M11370, combination versus saline, p = 0.010 and tadalafil
versus saline, p = 0.045; M19129, combination versus saline,
p = 0.023). Interestingly, the analysis identified enriched
pathways and gene signatures associated with synaptic
transmission (M2923) through the genes upregulated in the
hippocampus of mice administered the combined therapy
(vorinostat and tadalafil, p = 0.042), but not the individual
treatments alone (vorinostat or tadalafil). This suggests that
the transcriptional consequences of targeting HDAC and
PDE5 together may underlie the recovery of memory func-
tion observed in the treated animals.
Discussion
There is convincing evidence that HDACs represent
suitable drug targets for therapeutic intervention of AD
[16, 20, 21]. However, their adverse side effects mean
they are not an option for chronic treatments [22].
While the administration of selective HDACIs represents
an attractive potential solution to this challenge [23],
counteracting their off-target effects may require sacri-
ficing some of the beneficial effects obtained with current
broad-spectrum HDACIs. However, the use of low doses
of pan-HDACIs in combination therapy could reduce
toxic side effects and might synergistically enhance effi-
cacy. Here, we demonstrate that the co-administration of
sub-effective doses of tadalafil, a safe and well-tolerated
specific PDE5 inhibitor, together with the HDACI, vorino-
stat, produces a synergistic effect that prevents the disrup-
tion in synaptic plasticity displayed in AD mice. The
amelioration in memory impairment exhibited by the
treated Tg2576 mice was accompanied by a significant re-
duction in amyloid and tau pathologies, and the recovery
of dendritic spines. Indeed, this combination therapy in-
duces a distinct transcriptional profile in the hippocampus
of transgenic mice that may underlie the restoration of the
AD phenotype.
Chromatin remodelling due to changes in histone
acetylation induces the transcription of genes that en-
code proteins involved in the growth of new synapses
and the increase in synaptic strength [24, 25]. The en-
hancement of hippocampus-dependent memories by
HDACIs required CREB and its interaction with CBP
[10]. Indeed, a novel HDACI, crebinostat, enhances
memory in mice by facilitating CREB-dependent tran-
scription [11]. Here, we demonstrate a synergistic effect
of vorinostat and tadalafil in the induction of the epigen-
etic response (AcH3K9 levels), suggesting that both the
pathways affected by these inhibitors may interact at
some point. By elevating cGMP levels, PDE5 inhibition
may also produce CREB activation and the recruitment
of CBP, a histone acetyltransferase capable of altering
chromatin structure [26]. This mechanism could be re-
sponsible for restoring LTP and enhancing memory, as
observed when the combination of vorinostat and
tadalafil was administered to AD transgenic mice.
Moreover, the fact that the reversion of memory defi-
cits and synapse loss in aged Tg2576 mice was main-
tained even after a washout period of 4 weeks suggests
that targeting HDAC and PDE5 simultaneously trig-
gers long-lasting changes in plastic remodelling that
may be particularly interesting to counteract memory
decline in AD.
GSEA data show that the pathways associated with
synaptic plasticity are affected by combined treatment
with vorinostat and tadalafil and that these effects may
be responsible for enhancing memory in Tg2576 mice by
augmenting the expression of genes involved in synaptic
transmission. The restoration of LTP in APP/PS1 slice
mice administered these two inhibitors supports this hy-
pothesis. Interestingly, using a theoretical-biological model
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that simulates the induction of LTP and of Rubinstein-
Taybi syndrome (RTS)-induced LTP deficits, it was pre-
dicted that the combination of HDAC and PDE inhibitors
would rescue LTP deficits in the RST model [27]. Our
results verify the beneficial synergistic effects predicted by
this theoretical model.
With regard to AD markers, a reduction in tau path-
ology was observed in all the mice that received the inhib-
itors, alone or in combination. Indeed, PDE5 inhibition
through the regulation of the Akt/GSK3β pathway is
believed to decrease pTau levels [17, 28]. Moreover, the
activity of vorinostat on HDAC6 (IC50 10 nM) increases
α-tubulin acetylation, possibly one of the mechanisms
involved in the amelioration of the tau pathology [29, 30].
Evidence is accumulating that α-tubulin acetylation plays
a critical role in the clearance of misfolded and aggregated
proteins, since it has been shown to influence aggresome
formation as a means of cell protection [31, 32]. Thus, the
inhibitory effect of vorinostat on HDAC6 is also likely
to participate in the amelioration of amyloid pathology
observed with the combination therapy [33, 34]. Never-
theless, a synergistic effect on the transcription of genes
involved in amyloid production and/or clearance
should also be considered since no effect was observed
in the mice that receive vorinostat alone (pan-HDAC
inhibitor). Thus, further studies will be necessary to
explore the mechanisms involved in the reduction of
amyloid and tau pathologies.In summary, the concomi-
tant inhibition of HDAC and PDE5 shown in this study
may reverse AD-related pathology through different
mechanism of action, some of which remain to be ex-
plored (Fig. 5).
Conclusions
In summary, we propose a new therapeutic approach
with potential to treat AD that simultaneously targets
HDAC and PDE5. This synergism may make it possible
to achieve more optimal safety profiles for HDACIs,
making them suitable for chronic treatments. On the
one hand, this study suggests that potent HDAC inhib-
ition is not necessary to obtain an efficacious functional
response (H3K9 acetylation), and on the other hand, if
the changes induced in gene expression underlie the
recovery of memory, then simply activating specific gene
programmes might be sufficient. Accordingly, molecules
with a short half-life and residence time might even pro-
duce optimal therapeutic effects. Hence, this may just be
the starting point to design and identify molecules with
adequate dual activity and that are both efficacious and
safe. Moreover, the data presented validate the use of a
systems therapeutics approach to drug discovery.
Methods
Drugs
For in vitro studies, tadalafil (Euroasian Chemicals Pri-
vate Ltd., Mumbai, India) and vorinostat (Cayman
Chemical Company, Ann Arbor, MI, USA) were dis-
solved in DMSO at 10 mM and to final concentrations
in medium cell. For in vivo studies, tadalafil (Cialis, Eli
Lilly & Company) was administered in vivo by oral
Class I HDAC 
(HDAC2, HDAC1, HDAC3)
PDE5
PKG-Ca+2
cGMP
LTP
Memory
Plasticity-related gene 
transcription
Dendritc spine density
pGSK3 -Ser9
Tau pathology A pathology
Intracellular transport
Cytoskeletal stability
Ac- -tubulin 
Class IIb
(HDAC6)
Combination
vorinostat + tadalafil
CRE
CREB
PCB
P
CREB
PCB
P
CB
P
HAT
CREB
P
Ac Ac
Fig. 5 Putative mechanism of action involved in the restoration of pathological signs by the simultaneous inhibition of HDACs and PDE5. HDAC
histone deacetylase, Ac acetyl, PDE phosphodiesterase, PKG protein kinase G, LTP long-term potentiation, inhibition, activation
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gavage at a dose of 1 mg/kg and was prepared as previ-
ously described [17]. Vorinostat was administered intra-
peritoneally (i.p.) at a dose of 12.5 mg/kg and was
dissolved in 10 % DMSO, 10 % Tween-20 and 90 %
saline solution.
Primary neuronal cultures and treatments
Primary neuronal cultures were obtained from the
hippocampus of embryonic day 16 (E16) wild-type (WT)
mice and used at 15 days in vitro (DIV) [35]. Cultures
were treated for 2 h with tadalafil, vorinostat or the
combination of vorinostat and tadalafil at different con-
centrations during 2 h. For Western blot analysis, hippo-
campal neurons were collected after the different
treatments in a cold lysis buffer with protease inhibitors
[35].
Acetyl-Histone H3 Lysine 9 (H3K9ac) cellular detection
assay (AlphaLisa technology)
Briefly, 2000 cells (SH-SY5Y) were plated in a poly-D-ly-
sine-treated 384-well plate. Cells were incubated with
different concentrations of vorinostat and tadalafil dur-
ing 2 h. After incubation, the medium was removed and
cells were lysed, histones were extracted and histone car-
rying the acetylation mark was detected following the
manufacturer’s instructions (PerkinElmer; Cat number
AL714 A/C kit assay). Signal of acetylation mark was ob-
tained after 18 h of dark incubation at room temperature
and was normalized by the unmodified histone signal
and calculated as folds over basal levels, considered as
those obtained in the absence of assayed compounds.
Slice recordings
Hippocampal slices from APP/PS1 mice, positive and
WT littermate mice (6–9 months) were stimulated with
bipolar electrodes and recorded with a glass microelec-
trode placed on the stratum radiatum of the hippocampal
CA1 region to monitor extracellular postsynaptic field po-
tentials (fPSPs). Baseline responses were recorded and test
stimuli given at 0.1 Hz. Slope of fPSP was analyzed before
and after high-frequency stimulation protocol. See the
Additional file 1: Additional methods for further details.
Animals and chronic treatments
Transgenic mice (Tg2576) overexpressing human amyl-
oid precursor protein (hAPP) carrying the Swedish
(K670N/M671L) familial AD mutation under control of
the prion promoter [36] were used. Mice were on an
inbred C57BL/6/SJL genetic background. Animals were
housed four to five per cage with free access to food and
water, and maintained in a temperature-controlled envir-
onment on a 12-h light-dark cycle. Tg2576 female mice
(14–16 months old) were treated once daily with tadalafil
(1 mg/kg, p.o.), vorinostat (12.5 mg/kg, i.p.), tadalafil (1 mg/
kg, p.o.) + vorinostat (12.5 mg/kg, i.p.) (this treatment will
be defined as combination therapy), or vehicle for 4 weeks.
Behavioural and biochemical studies were performed com-
paring transgenic mice to age- and strain-matched trans-
genic negative littermates (WT).
Behavioural studies
Behavioural studies were carried out during light time
(from 9 a.m. to 2 p.m.). Protocols were approved by the
Ethical Committee of the University of Navarra (in ac-
cordance with the European and Spanish Royal Decree
1201/2005).
Fear conditioning test (FC)
To evaluate the effects of drugs on cognitive function
after 2 weeks of treatment, fear conditioning paradigm
was used as described in [18]. Freezing scores were
expressed as percentages. The conditioning procedure
was carried out in a StartFear system (Panlab S.L.,
Barcelona, Spain).
Morris water maze test (MWM)
After 3 weeks of treatment, we used the MWM test to
evaluate the working and reference memory function in
Tg2576 mice, as previously described [17]. In addition,
after a 4-week washout period of the drugs, a reversal
phase of MWM was carried out. In this phase, the plat-
form was placed in the opposite quadrant of the tank,
and the hidden platform training during five consecutive
days (four trials per day) was performed. All cues
remained in their original positions. Memory retention
was analyzed in a probe at day 6. All experimental pro-
cedures were performed blind to groups. Animals were
euthanized 24 h after the last probe. One hippocampus
of three animals per group (vehicle, vorinostat, tadalafil
and the combination) was used for RNA extraction,
Affymetrix microarray hybridization and data analysis
(see Additional file 1: Additional methods).
Determination of Aβ levels
Parieto-temporal cortical Aβ42 levels were measured by
using a sensitive sandwich ELISA kit (Invitrogen, Camarillo,
CA). We measured Aβ42 pool containing intracellular and
membrane-associated Aβ42 that may be more closely
related to the expression of AD signs than other measured
Aβ42 species [37]. The tissue was homogenized in a buffer
containing SDS 2 %, Tris-HCl (10 mM, pH 7.4), protease
inhibitors (Complete Protease Inhibitor Cocktail, Roche)
and phosphatase inhibitors (0.1 mM Na3VO4, 1 mM NaF).
The homogenates were sonicated for 2 min and centrifuged
at 100,000×g for 1 h. Aliquots of supernatant were directly
diluted and loaded onto ELISA plates in duplicate. The
assays were performed according to the manufacturer’s
instructions.
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Immunoblotting
For Western blot analysis of APP-derived fragments, SDS
2 % protein extracts were separated in a CriterionTM
Tris-Tricine 10–20 % gradient precast gel (Bio-Rad,
Hercules, CA, USA). For analysis of pTau and Tau, pro-
teins were separated in a Criterion TM Bis-Tris 4–12 %
gradient precast gel (Bio-Rad, Hercules, CA, USA). For
further details, see Additional file 1: Additional methods.
Dendritic spine measurements
A modified Golgi-Cox method was used [18, 38]. For
each mouse (n = 4 per group), nine neurons (three den-
dritic segments were measured per neuron, at least 30
μm long) were analyzed.
Data analysis and statistical procedures
The data was analyzed with SPSS for Windows, version
15.0 (SPSS, Chicago, IL, USA), and unless otherwise
indicated, the data is expressed as means ± standard
error of the mean (S.E.M.). Normal distribution of data
was checked by the Shapiro-Wilk test.
In the MWM, latencies to find the platform were
examined by a two-way repeated measures ANOVA test
(genotype × trial) to compare the cognitive status in WT
mice and Tg2576 mice. Likewise, the treatment effect in
spatial memory was examined also by a two-way repeated
measures ANOVA test (treatment × trial) followed by post
hoc Scheffe’s analysis. In those cases where no interaction
was found between factors, the F value associated to geno-
type or treatment main effect will be shown. When two
groups were compared, Student’s t test was used, whereas
when more than two experimental groups were compared,
one-way ANOVA followed by post hoc Scheffe’s test was
used. Each biochemical assay was repeated, at least, three
times, and the data were analyzed using one-way ANOVA
followed by post hoc Scheffe’s test.
Additional file
Additional file 1: Additional methods. Table S1. Pharmacokinetic
parameters and blood-brain barrier permeability for vorinostat and tadalafil.
Figure S1. Mean plasmatic concentration evolution versus time after
different administrations of vorinostat (SAHA, 12.5 mg/kg, i.p. administration)
(a), tadalafil (1 mg/kg, oral administration) (b) and concomitant
vorinostat and tadalafil administration (12.5 mg/kg, i.p. administration,
and 1 mg/kg, oral administration, respectively) (c). Figure S2. Memory
tests after chronic treatment with vehicle in non-transgenic mice (WT)
compared to transgenic mice (Tg2576). Figure S3. (a) Representative
Western blot bands using the AT8 (pTau) antibody normalized to total
tau (T46) in cortical tissues of WT and Tg2576 animals treated with vehicle.
The histograms represent the quantification of the immunochemically reactive
bands in the Western blot. An increase in pTau levels in Tg2576 mice receiving
vehicle are shown compared to WT-vehicle mice. Results are expressed as
mean ± SEM (n= 8–10 in each group) (**p≤ 0.01). (b) Representative Golgi
staining images of the apical dendrites on CA1 hippocampal pyramidal
neurons in WT and Tg2576 animals treated with vehicle. Scale bar:
10 μm. WT vehicle group showed a significantly higher level in the
spine density of apical dendrites on hippocampal CA1 pyramidal neurons
than Tg2576 vehicle mice (n = 34–36 neurons; ***p≤ 0.001). (PDF 270 kb)
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